• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Santen, Tracon ink ophthalmology agreement

Santen, Tracon ink ophthalmology agreement

March 5, 2014
CenterWatch Staff

Tracon Pharmaceuticals and Santen Pharmaceutical have entered into an exclusive agreement for the development and global commercialization of Tracon's anti-endoglin antibodies, including TRC105, in ophthalmology. Preclinical and clinical data from Tracon's ongoing development of TRC105, in combination with anti-VEGF products in oncology, indicate inhibiting both the endoglin and VEGF pathways has the potential to show advantages over inhibiting VEGF alone in the treatment of conditions such as wet age-related macular degeneration (wet AMD).

Santen will make a $10 million upfront payment and certain milestone payments to Tracon in the development phase, and will pay commercialization milestones and tiered royalties on global sales of TRC105 in ophthalmology. Santen will fund 100% of all global development, and commercialization activities, including the initiation of IND-enabling studies. Tracon will continue ongoing phase II development of TRC105 in a number of oncology indications and will retain global rights on applications of its anti-endoglin antibody portfolio outside of ophthalmology.

"TRC105 has the potential to help patients suffering from serious and debilitating eye diseases who do not benefit from current treatment," said Charles Theuer, M.D., Ph.D., president and CEO of Tracon. "The experience Tracon has gained in the development of TRC105 in oncology, by combining TRC105 with bevacizumab and other inhibitors of the VEGF pathway, reinforces our belief that development of TRC105 in serious angiogenesis-driven eye diseases is an outstanding product development opportunity."

"Santen is committed to delivering novel medicines for the treatment of high unmet need ophthalmic conditions on a global basis. Currently, treatment options for retinal disease, including wet AMD are limited and, thus, Santen is pleased to gain access to novel compounds such as TRC105, so that Santen can contribute to improving the quality of life of patients suffering from retinal disease such as wet AMD," said Akira Kurokawa, president and CEO of Santen.

The TRC105 oncology development program includes two ongoing, randomized phase IIb studies with bevacizumab in renal cell carcinoma and glioblastoma, and combination studies with axitinib in renal cell carcinoma, with pazopanib in advanced soft tissue sarcoma and with sorafenib in hepatocellular carcinoma.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing